<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00394030</url>
  </required_header>
  <id_info>
    <org_study_id>GLP107724</org_study_id>
    <nct_id>NCT00394030</nct_id>
  </id_info>
  <brief_title>Injection Site Study In Patients With Type 2 Diabetes Mellitus (T2DM) And Healthy Volunteers</brief_title>
  <official_title>An Open-Label, Randomized, Multi-Site Study to Assess the Pharmacokinetics of Single Subcutaneous Injections of 16mg and 64mg of GSK716155 Administered at Three Different Injection Sites in Adult Male and Female Subjects With Type 2 Diabetes and of Single Subcutaneous Injections of 16mg and 64mg of GSK716155 Administered in the Abdomen of Healthy, Normal Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study is an open-label study in healthy volunteers and in patients with Type 2 Diabetes
      Mellitus to assess safety and tolerability parameters, the levels of GSK716155 in the
      bloodstream after a single dose given at different injection sites, and the impact this
      medication has on various substances in the blood. Assessments include ECGs, vital signs,
      repeat blood sampling and monitoring of any side effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An Open-Label, Randomized, Multi-Site Study to Assess the Pharmacokinetics of Single
      Subcutaneous Injections of 16mg and 64mg of GSK716155 Administered at Three Different
      Injection Sites in Adult Male and Female Subjects with Type 2 Diabetes and of Single
      Subcutaneous Injections of 16mg and 64mg of GSK716155 Administered in the Abdomen of Healthy,
      Normal Volunteers
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 16, 2006</start_date>
  <completion_date type="Actual">March 20, 2007</completion_date>
  <primary_completion_date type="Actual">March 20, 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic measurements for different injection sites after one dose.</measure>
    <time_frame>Pre-dose, 6, 24, 48, 96, 216, 312, 480, 672 and 984 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic measurements at three different times after one dose.</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Group A healthy subjects will be randomized to receive 16 milligram (mg) of GSK716155 to abdomen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Group B healthy subjects will be randomized to receive 64 mg of GSK716155 to abdomen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Group C Type II diabetes subjects will be randomized to receive 16 mg of GSK716155 to abdomen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Group D Type II diabetes subjects will be randomized to receive 16 mg of GSK716155 to arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Group E Type II diabetes subjects will be randomized to receive 16 mg of GSK716155 to leg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Group F Type II diabetes subjects will be randomized to receive 64 mg of GSK716155 to abdomen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Group G Type II diabetes subjects will be randomized to receive 64 mg of GSK716155 to arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group H</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Group H Type II diabetes subjects will be randomized to receive 64 mg of GSK716155 to leg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK716155 subcutaneous injections</intervention_name>
    <description>GSK716155 will be available as lyophilize uniform cake in 10 milliliter (mL) clear glass vials with 20 millimeter (mm) closure. Subjects will administer dose of either 16mg or 64mg of GSK716155 via subcutaneous injection(s). For dose of 16 mg 1 injection of 0.62 mL will be administered and for dose of 64 mg 3 injections of 0.82 mL each will be administered.</description>
    <arm_group_label>Group G</arm_group_label>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_label>Group H</arm_group_label>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  They can be healthy volunteers or subjects with type 2 diabetes mellitus that has been
             diagnosed for at least three months. T2DM subjects must be taking either (1) no
             medication for their diabetes or (2) taking metformin or (3) taking a TZD
             (thiazolidinedione).

          -  Subjects must have a BMI between 25 and 40 kg/mÂ² and weigh at least 50kg.

          -  Women must be of non-childbearing potential.

        Exclusion criteria:

          -  Bloodwork that meets certain criteria (for example, total cholesterol &gt; 240 mg/dL)

          -  Clinically significant hepatic enzyme elevation

          -  HbA1c less than 6.5 or greater than 10

          -  Positive test result for Hepatitis B surface antigen, positive Hepatitis C or HIV

          -  Any major illness other than diabetes

          -  Previous use of insulin as treatment for diabetes

          -  Significant renal disease as defined by screening lab tests

          -  History of drug or other allergy which in the opinion of the investigator contradicts
             subject participation

          -  Smoking or use of nicotine-containing products within the previous 6 months

          -  History of alcohol or drug abuse

          -  Unwilling to abstain from alcohol prior to and during the in-patient clinic stays

          -  Unwilling to abstain from caffeine- or xanthine-containing products prior to and
             during the in-patient clinic stays

          -  Use of St. John's Wort during the study

          -  Has donated 500 nL or more blood within 56 days of dosing or plans to donate blood in
             the month following study participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Morrisville</city>
        <state>North Carolina</state>
        <zip>27560</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.gsk-clinicalstudyregister.com/study/GLP107724?search=study&amp;search_terms=GLP107724#rs</url>
    <description>Results for study GLP107724 can be found on the GSK Clinical Study Register.</description>
  </link>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2006</study_first_submitted>
  <study_first_submitted_qc>October 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2006</study_first_posted>
  <last_update_submitted>September 8, 2017</last_update_submitted>
  <last_update_submitted_qc>September 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GSK716155 pharmacodynamics pharmacokinetics injection site</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>GLP107724</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>GLP107724</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>GLP107724</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>GLP107724</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>GLP107724</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>GLP107724</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>GLP107724</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

